List view / Grid view

News

Janssen submits application to EMA to expand use of ibrutinib

4 November 2015 | By Victoria White

Janssen-Cilag International has submitted a Type II variation application to the European Medicines Agency (EMA), which seeks to broaden the existing marketing authorisation for Imbruvica (ibrutinib) to include previously untreated patients with chronic lymphocytic leukaemia (CLL).

Phase III study of avelumab in NSCLC starts

4 November 2015 | By Victoria White

Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody that potentially uses the body’s own immune system to fight cancer...

7th Global Healthcare Conference

3 November 2015 | By London Business School

The Future of Healthcare - striking a balance between patients, value and innovation. Monday 7 December 2015...